Actualización de la Guía Mexicana para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología

Cardiel, Mario H.; Díaz-Borjón, Alejandro; Mercado, Mónica Vázquez-Del; Gámez-Nava, Jorge I.; Fabris, Leonor Adriana Barile; Pacheco‐Tena, César; Torre, Luis H. Silveira; Ramos, Virginia Pascual; Robles, María Victoria Goycochea; Arreola, Jorge Enrique Aguilar; Díaz, Verónica; Nemegyei, José Álvarez; González-López, Laura del Carmen; Páramo, Mario Salazar; Hernández, Margarita Portela; Colín, Zully Castro; Friedman, Daniel; Hernández, Everardo Álvarez; Vargas, Julio Casasola; Hernández, Miguel Cortés; Flores-Alvarado, Diana Elsa; Martínez, Laura Arroyo; Vega‐Morales, David; Flores‐Suárez, Luis Felipe; Ramírez, Gabriel Medrano; Cruz, Antonio Barrera; González, Adolfo García; López, Susana Marisela López; Reyes, Alejandra Rosete; Morales, Rolando Espinosa

doi:10.1016/j.reuma.2013.10.006

Cited by 44 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the Mexican guidelines of the treatment for RA used in our hospital, the patients may receive as first option MTX as monotherapy or may initiate a combined therapy with MTX plus a biological agent (usually an anti-TNF agent) specially if the patient is considered with inadequate therapeutic response after at least 3 months of monotherapy with MTX or another DMARD [15]. Therefore, the rheumatologists in the clinical visit decided to institute a therapeutic strategy independently of this study.…”

Section: Methodsmentioning

confidence: 99%

Modifications in Lipid Levels Are Independent of Serum TNF-α in Rheumatoid Arthritis: Results of an Observational 24-Week Cohort Study Comparing Patients Receiving Etanercept Plus Methotrexate or Methotrexate as Monotherapy

Rodriguez-Jimenez

Garcia-Gonzalez

Ayala-Lopez

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Objective. To compare the modifications in lipids between patients with rheumatoid arthritis (RA) receiving etanercept plus methotrexate (ETA + MTX) versus methotrexate (MTX) and their relationship with serum levels of tumor necrosis factor-alpha (TNF-α). Methods. In an observational cohort study, we compared changes in lipid levels in patients receiving ETA + MTX versus MTX in RA. These groups were assessed at baseline and at 4 and 24 weeks, measuring clinical outcomes, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, and TNF-α. Results. Baseline values for lipid levels were similar in both groups. HDL-C levels increased significantly only in the ETA + MTX group (from 45.5 to 50.0 mg/dL at 4 weeks, a 10.2% increase, P < 0.001, and to 56.0 mg/dL at 24 weeks, a 25.1% increase, P < 0.001), while other lipids underwent no significant changes. ETA + MTX also exhibited a significant increase in TNF-α (44.8 pg/mL at baseline versus 281.4 pg/mL at 24 weeks, P < 0.001). The MTX group had no significant changes in lipids or TNF-α. Significant differences in HDL-C between groups were observed at 24 weeks (P = 0.04) and also in TNF-α (P = 0.01). Conclusion. HDL-C levels increased significantly following treatment with ETA + MTX, without a relationship with decrease of TNF-α.

show abstract

Section: Methodsmentioning

confidence: 99%

Modifications in Lipid Levels Are Independent of Serum TNF-α in Rheumatoid Arthritis: Results of an Observational 24-Week Cohort Study Comparing Patients Receiving Etanercept Plus Methotrexate or Methotrexate as Monotherapy

Rodriguez-Jimenez

Garcia-Gonzalez

Ayala-Lopez

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…It is estimated that the direct medical cost in dollars of RA in Mexico is US$ 2334, and the cost from the patient’s own pocket is US$ 610. Reports have revealed that 15 % of the family income goes towards RA expenses, which can be disastrous on the economy of any family [ 9 ].…”

Section: Barriers Preventing Access To Health Care In the Current Heamentioning

confidence: 99%

Challenges faced in Latin America for the implementation of an ideal health-care model for rheumatoid arthritis patients: are we ready?

2015

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic, inflammatory, progressive disease characterized by inflammation of the synovial tissue. It results in the severe functional deterioration of the joints involved and the incapacity to work. Our main aim is to determine the characteristics of the current health-care models used in treating rheumatoid arthritis patients in Latin America. We want to analyze the details, using them as the foundation to create an ideal health-care model that is focused on the patient. We have revised documents, including guides to clinical practice, monitoring models and health-care models according to the current policies and resources available in various Latin American countries. Based on this information, the qualities and deficiencies of the current models will be analyzed, in order to use this as a basis on which to construct a proposed health-care model that covers the specific needs of rheumatoid arthritis patients, considering the resources of each population. Despite the collapse seen in many health systems throughout history, we can learn from them and should develop a new model starting from the path pursued, capitalizing on our experiences, teachings, and errors committed. However, in most cases, the obstacles to the success of the systems do not lie in the fundamental structure or the “spirit of the legislator” but rather in the day-to-day development within the community and the special interest of each agent in a system.

show abstract

“…Расширение знаний об иммунопатогенезе ИВРЗ и роли JAK в регуляции иммунного ответа и воспаления создали предпосылки для изучения эффективности ТОФА при других ИВРЗ и «неревматических» иммуновоспалительных заболеваний [3,4,[11][12][13][14]. ТОФА классифицируется как «таргетный» синтетический базисный противовоспалительный препарат (тсБПВП) [15] и включен в международные [16][17][18][19][20][21][22][23][24][25] и российские [26] клинические рекомендации по лечению РА, а также в рекомендации Американской коллегии ревматологов (ACR) по лечению ПсА [27].…”

unclassified

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)

Насонов

Авдеева²,

Лила

2020

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Расшифровка механизмов патогенеза иммуновоспалительных ревматических заболеваний (ИВРЗ), основными формами кото-рых являются ревматоидный артрит (РА), спондилоартриты (СпА), включающие анкилозирующий спондилит (АС) и псориатиче-П р о г р е с с в р е в м а т о л о г и и в X X I в е к е Насонов Е.Л.научный руководитель ФГБНУ «НИИР им. В.А. Насоновой», академик РАН, профессор, докт. мед. наук 1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»,

show abstract

Actualización de la Guía Mexicana para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología

Cited by 44 publications

References 32 publications

Modifications in Lipid Levels Are Independent of Serum TNF-α in Rheumatoid Arthritis: Results of an Observational 24-Week Cohort Study Comparing Patients Receiving Etanercept Plus Methotrexate or Methotrexate as Monotherapy

Modifications in Lipid Levels Are Independent of Serum TNF-α in Rheumatoid Arthritis: Results of an Observational 24-Week Cohort Study Comparing Patients Receiving Etanercept Plus Methotrexate or Methotrexate as Monotherapy

Challenges faced in Latin America for the implementation of an ideal health-care model for rheumatoid arthritis patients: are we ready?

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)

Contact Info

Product

Resources

About